ASCO '14: What's on Tap for Saturday
) -- I've landed in this great Midwestern city to attend and cover American Society of Clinical Oncology (ASCO) annual meeting. I'll be posting stories throughout the weekend and into Monday, so check my landing page on TheStreet
for links. I'll be tweeting frequently from the ASCO data presentations, too, so follow me on Twitter at @adamfeuerstein
I tend to keep my ASCO reporting schedule loose for maximum flexibility, but here's a rough idea of what you'll see and when from companies with a significant presence during Saturday's session.
ASCO media embargoes lift at 7:30 am ET on data from Eli Lilly's
(LLY - Get Report)
ramucirumab phase III study in non-small cell lung cancer (abstract no. LBA8006) and Pharmacyclics
(PCYC - Get Report)
and Johnson & Johnson's
phase III study comparing Imbruvica to Glaxo's
Arzerra in relapsed/refractory chronic lymphocytic leukemia. (The "RESONATE" study, abstract no. LBA7008.)
Both of these studies will be featured at an ASCO media briefing starting Saturday at 9 am ET. The actual Lilly ramucirumab data presentation at ASCO isn't until Monday, while Pharmacyclics' Imbruvica RESONATE data is presented on Tuesday. [Yes, this is confusing, but ASCO's data release policy can get funky at times.]
I'm skipping the ASCO media briefing Saturday morning to attend the dueling oral presentations for the competing T790-mutant lung cancer drugs from AstraZeneca
(AZN - Get Report)
and Clovis Oncology
, respectively. Those presentations start at 9 am ET, I'll tweet as many slides from the presentations as I can. Much of the AstraZeneca data have been disclosed already
, but we'll get a meaningful update on the Clovis drug tomorrow.
The other significant Saturday oral presentations features PD-1 immunotherapy data in kidney cancer from Bristol-Myers Squibb
. Those start at 4 pm ET.
There is also a lung cancer poster session Saturday afternoon featuring data from Bristol, Ariad Pharma
and Merrimack Pharma
has an oral presentation on selinexor data Saturday, as well.